Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin Against Biofilm-Forming Enterococcus faecalis or E. faecium in an In Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations and an In Vivo Survival Assay Using Galleria mellonella Larvae

Megan K. Luther

Marios Arvanitis

The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our Terms of Use.

Citation/Publisher Attribution
Available at: http://dx.doi.org/10.1128/AAC.02790-13
Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin against Biofilm-forming Enterococcus faecalis or E. faecium in an In Vitro Pharmacodynamic Model using Simulated Endocardial Vegetations and In Vivo Survival Assay using Galleria mellonella Larvae

May 12, 2014

Megan K. Luther¹,², Marios Arvanitis³,⁴, Eleftherios Mylonakis³,⁴, Kerry L. LaPlante¹,²,³*

University of Rhode Island, Department of Pharmacy Practice¹, Rhode Island Infectious Diseases (RIID) Research Program Laboratory, Providence Veterans Affairs Medical Center², Division of Infectious Diseases, Warren Alpert Medical School of Brown University³, Rhode Island Hospital⁴, Providence, RI

*Corresponding Author: Kerry L. LaPlante, Pharm.D. Associate Professor of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881, office: 401-874-5560; e-mail: KerryLaPlante@uri.edu

Abstract Count: 245

Key words (MESH): biofilm, daptomycin, gentamicin, linezolid, rifampin, Enterococcus faecalis, Enterococcus faecium, vancomycin resistance, and Galleria mellonella
Abstract Enterococci are the third most frequent cause of infective endocarditis. A high-
inoculum stationary phase in vitro pharmacodynamic model with simulated endocardial
vegetations was used to simulate human pharmacokinetics of daptomycin 6 or 10mg/kg/day,
or linezolid 600mg q12h alone and in combination with gentamicin 1.3mg/kg q12h, rifampin
300mg q8h or 900mg q24h. Biofilm-forming vancomycin-susceptible Enterococcus faecalis
and vancomycin-resistant E. faecium (VRE) were tested. At 24, 48 and 72h, all daptomycin-
containing regimens demonstrated significantly more activity (decline in CFU/g) than any
linezolid-containing regimen against biofilm-forming E. faecalis. The addition of gentamicin
to daptomycin (6 and 10mg/kg) in the first 24 hours significantly improved the bactericidal
activity. In contrast, addition of rifampin delayed the bactericidal activity of daptomycin
against E. faecalis; and against VRE, antagonized all regimens at 24h. Also, against VRE,
addition of gentamicin to linezolid at 72h improved activity and was bactericidal. Rifampin
significantly antagonized the activity of linezolid against VRE at 72h. In in vivo Galleria
mellonella survival assays, linezolid and daptomycin improved survival. Daptomycin 10mg/kg
improved survival significantly over linezolid against E. faecalis. Addition of gentamicin
improved efficacy of daptomycin against E. faecalis and linezolid and daptomycin against
VRE. We conclude that in enterococcal infection models, daptomycin has more activity than
linezolid alone. Against biofilm-forming E. faecalis, the addition of gentamicin in the first 24h
causes the most rapid decline in CFU/g. Of interest, addition of rifampin delayed or
antagonized activity of daptomycin against biofilm-forming E. faecalis and VRE respectively
in the first 24h.
Introduction.

Despite major advances in medicine and surgery, infective endocarditis (IE) remains a concerning disease associated with considerable morbidity and mortality. Bacterial causes of IE and bacteremia have changed over the past few decades and now streptococci, staphylococci, and enterococci have emerged as the major pathogens. Among these, Enterococcus has become the most challenging to treat. Barriers in treating these infections include the need for multiple agents to demonstrate bactericidal activity and microbiological cure; biofilm production among these bacteria; and resistance to the mainstays of therapy (i.e., ampicillin, penicillin, and vancomycin). Biofilm production in enterococci is common in *E. faecalis*, with worldwide rates reported between 26-100%, and 93% reported in the US. The 2005 American Heart Association recommendations for drug-resistant enterococcal IE include linezolid and quinupristin-dalfopristin, which are both bacteriostatic against enterococci.

Daptomycin, at high doses, demonstrates bactericidal activity against enterococci in other types of infection, and against *S. aureus* in endocarditis. This is due to daptomycin’s mechanism of action as it disrupts the cell-membrane potential and is growth phase independent. There is promising data demonstrating in vitro synergy with gentamicin and daptomycin combination therapy against VRE, and case reports also support these findings. Therefore, the addition of gentamicin, a ribosomal active agent may provide a synergistic approach in VRE IE infections. Additionally, since *E. faecalis* often produce biofilm, it is of interest to evaluate daptomycin’s activity in combination with rifampin. Finally, since daptomycin demonstrates concentration-dependent killing, evaluation of approved doses (6mg/kg) and higher doses (10mg/kg) may result in increased activity and resistance prevention, as there is established efficacy in other infection types with appropriate safety data.
We therefore evaluated the in vitro activity of daptomycin and linezolid alone and in combination with gentamicin or rifampin against enterococci in an in vitro model with sequestered high inoculum stationary phase infection using simulated endocardial vegetations (SEV). (20, 22, 23) We also tested these regimens in an in vivo survival assay using Galleria mellonella larvae. We used a vancomycin-susceptible biofilm-producing E. faecalis and a vancomycin-resistant E. faecium. We also evaluated biofilm production of these isolates.
MATERIALS AND METHODS

**Bacterial strains.** We evaluated a vancomycin-susceptible, ampicillin-susceptible *E. faecalis*, ATCC 29212 (also gentamicin-susceptible and rifampin-susceptible) and a vancomycin-resistant (VRE) *E. faecium* clinical isolate from the Providence Veterans Affairs Medical Center (also penicillin-resistant, gentamicin-susceptible, and rifampin resistant). Both isolates were linezolid and daptomycin susceptible.

**Antimicrobial agents.** Linezolid (lot# 11C03U04, 10H10Z16; Pfizer, Inc.; NY) was obtained commercially, and daptomycin was obtained from Cubist Pharmaceuticals, Inc., (Lexington, MA). Rifampin (lot 085K1929) and gentamicin (lot 050K03421, 097K06887V) were purchased from Sigma Chemical Company (St. Louis, MO). Stock solutions of each antibiotic were freshly prepared at the beginning of each week and kept frozen at -4°C.

**Medium.** As previously described, Mueller-Hinton broth (Becton Dickinson, Sparks, MD) supplemented with calcium and adjusted to physiologic conditions of 50 mg/L calcium chloride (ionized Ca; 1.03-1.23 mmol/L) and 12.5 mg/L magnesium was used for all susceptibility analyses and in vitro pharmacodynamic analyses.(24) Bacto Tryptic Soy Broth (TSB; Becton Dickinson) supplemented with 1% glucose and 50 mg/L calcium chloride was used to optimize biofilm production in the biofilm assay.(25, 26) Colony counts were determined using Tryptic Soy Agar (TSA, Difco, Becton Dickinson). For the in vivo study, strains were grown overnight at 30°C in brain heart infusion (BHI) with agitation. Inoculum was confirmed by plating serial dilutions on BHI agar.

**Susceptibility.** Minimum inhibitory concentrations (MICs) and minimum bactericidal concentration (MBC) testing was determined at both standard (~10^6 CFU/mL) and high inoculum (~10^9 CFU/mL) in triplicate using microbroth dilution according to CLSI methods.(27). All samples were incubated at 35°C for 24 hours prior to interpretation of results.
Biofilm Formation. In growth conditions (media; see above) that optimize biofilm production in Enterococcus, quantification of biofilm formation was conducted using the microtiter plate assay first described by Christensen et al. (28) and modified as follows. Briefly, stationary cultures of an overnight growth of the Enterococcal strains (1% vol/vol) were diluted into fresh cation- and glucose-supplemented TSB. The inoculated medium was dispensed into wells of sterile flat-bottom 96-well polystyrene tissue culture plates (Costar no. 3596; Corning Inc., Corning, NY, USA). Biofilm production in Enterococcus has been linked to several genes including, fsr, gelE, and sprE.(29) Previous findings support that expression of these genes were found at 24h of growth.(29) We examined two sets of plates, incubated at 35ºC a minimum of 24h and 48h, respectively. The attached bacteria was then fixed and stained with crystal violet. After drying, the optical density (OD) of stained adherent bacterial films was read using a µQuant™ Microplate Spectrophotometer microtiter dish reader (BioTek Instruments, Inc. Winooski, Vermont, USA.). The optical density (OD) of bacterial films were classified into the following categories: no biofilm production, weakly (+), moderately (++), or strongly (+++) adherent, based upon the ODs of bacterial films (30). The test was carried out in triplicate. The results were averaged.

In vitro pharmacodynamic infection model with Simulated Endocardial Vegetations (SEVs). As previously described, organism stocks containing approximately $10^{10}$ CFU/mL were prepared by inoculating 5mL test tubes of normal saline with colonies harvested from fresh overnight growth on TSA.(20, 22, 24, 31, 32) SEVs containing $10^9$ CFU/g were prepared by combining 0.05mL of the organism suspension with 0.4mL of human cryoprecipitate antihemolytic factor (AHF) from volunteer donors (Rhode Island Blood Bank, Providence, RI), 0.05mL of aprotinin suspension, and 0.025 mL of platelet suspension (platelets mixed with normal saline, 250,000 to 500,000 platelets per clot) in 1.5 mL eppendorf tubes. Bovine thrombin (5,000 units/mL, 50 µL), was added to each tube after
insertion of a sterile monofilament line into the mixture. The resultant SEVs were removed from eppendorf tubes with a sterile 21-gauge needle and introduced into the model. This methodology results in SEVs containing approximately 3-3.5 g/dL of albumin and 6.8-7.4 g/dL of total protein (22).

**In vitro pharmacodynamic infection model.** An in vitro infection model consisting of a 250 mL one-compartment glass apparatus with ports where the SEVs are suspended, was utilized for all simulations. The apparatus was pre-filled with media and antibiotics were administered as boluses over a 72-hour period into the central compartment via an injection port. The models were placed in a 35°C water bath throughout the procedure with a magnetic stir bar for thorough mixing of the drug in the model. Fresh media was continuously supplied and removed from the model via a peristaltic pump (Masterflex, Cole-Parmer Instrument Company, Chicago, IL USA) set to simulate the half-lives of the antibiotics. Two SEVs were removed from each model at 0, 4, 8, 24, 32, 48, 56 and 72 hours. Once removed, SEVs were then immediately homogenized in trypsin, plated onto TSA, and incubated at 35°C for 24 hours before colony count enumeration. This method results in a lower limit of detection of $2.0 \ log_{10} \ CFU/g$ (23). Antimicrobial carryover was minimized by serial dilution (10-10,000) of plated samples in conjunction with vacuum filtration, when necessary, where samples were washed through a 0.22 µm filter with sterile water. These filters were then plated onto TSA and incubated at 35°C for 24 hours. Colonies were counted on filter paper; the limit of detection is $1.0 \ log_{10} \ CFU/g$.

Daptomycin was administered to simulate a 6mg/kg dose (peak, 98.6µg/mL) and 10mg/kg (141 µg/mL) every 24 hours (q24h) with pump rate set to achieve a half-life of 8 hours (21, 33). Linezolid was administered to simulate 600mg q12h with a half-life of 6 hours and a peak concentration 21 µg/mL.(27) Gentamicin was administered to simulate 1.3 mg/kg q12h (approximate: peak 6 µg/mL, trough 0.4µg/mL) a half-life of 2 hours.(24) Rifampin was
administered to simulate a dose of 300mg q8h (approximate peak 14.5 µg/mL) and a half-life of 4 hours. (24) Additionally, a regimen simulating rifampin 900mg once daily in combination with linezolid or daptomycin 6mg/kg was performed in duplicate to assess the effects of rifampin dosage schedule and concentration.

For combination regimen experiments the elimination rate was set for the drug with the shortest half-life, the drug with the longer half-life was supplemented. All model experiments were performed in triplicate unless otherwise noted, to ensure reproducibility. In addition, simulations in the absence of antibiotics were performed at the shortest half-life to assure adequate growth of the organisms in the model.

**Pharmacodynamic Analysis.** Reductions in log$_{10}$CFU/g over 72 hours were determined by plotting time-kill curves and compared between regimens. Bactericidal activity (99.9% kill) was defined as a $\geq 3\log_{10}$CFU/g reduction in colony count from the initial inoculum. Bacteriostatic activity was defined as a $< 3\log_{10}$ CFU/g reduction in colony count from the initial inoculum while inactive was defined as no observed reductions from initial inoculum. The time to achieve 99.9% kill was determined by non-linear regression (using a minimum of 4 data points) if $r^2 \geq 0.95$, or by visual inspection. Enhancement of activity was defined as an increase in kill of $\geq 2\log_{10}$ CFU/g by combination of antimicrobials versus the most active single agent of that combination. Improvement was defined as a 1 to $2\log_{10}$ CFU/g increase in kill in comparison to the most active single agent, while combinations that result in $\geq 1\log_{10}$ bacterial growth in comparison to the least-active single agent was considered to represent antagonism. The terms “improvement” and “enhancement” were used because our simulations involve therapeutically obtained serum concentration and this does not permit the mathematical modeling necessary to consider the standard terms “additivity” and “synergy” (34). Indifference was defined as $< 1\log_{10}$ CFU/g change in activity.
**Resistance.** Development of resistance was evaluated for each monotherapy and combination model at 24, 48, and 72 hours. MIC testing (using Etests) of daptomycin, linezolid, gentamicin and rifampin were conducted with isolates obtained from the 24, 48 and 72 hour time points to identify any MIC shifts. Plates were examined for growth after 24 hours of incubation at 35°C.

**Pharmacokinetic Analysis.** Samples for pharmacokinetic analyses were obtained through the injection port at 0.5, 1, 2, 4, 6, 8, and 24 hours for verification of target antibiotic concentrations. All samples were stored at -80°C until analysis. Daptomycin concentrations were determined by a previously described and validated HPLC method (Center for Anti-Infective Research and Development, Hartford, CT) (20). Gentamicin concentrations were determined by a homogeneous particle-enhanced turbidmetric immunoassay (PETIA; Architect, Multigent®; Abbott Diagnostics Abbott Park, IL, USA) at the Providence Veteran Affairs Medical Center. The gentamicin assay was known to have a range of detection of 0.3 to 10.0 µg/mL and a between day sample precision and percent coefficient of variation (CV%) of 1.35% and < 2.75%, respectively. Linezolid and rifampin concentrations were evaluated using HPLC (University of Florida, Gainesville, FL) as previously described (23, 24). Only single drug concentrations were evaluated, all in duplicate. The half-lives, maximum concentration (Cmax), and minimum concentration (Cmin) of the antibiotics were determined by the trapezoidal method utilizing PK Analyst software (Version 1.10, MicroMath Scientific Software, Salt Lake City, UT).

**In vivo Galleria mellonella survival assay.** Efficacy of daptomycin or linezolid in enterococcal infection was tested using *Galleria mellonella* survival assay. *Galleria mellonella* caterpillars at the final-instar stage of development were acquired from the vendor (Vanderhorst Wholesale Inc., St. Mary’s, OH) and used within 7 days of shipment. All experiments were performed according to previously described protocols with minor
modifications (35, 36). Sixteen larvae of appropriate weight (0.25-0.35g) were randomly selected to comprise each group. Larvae were inoculated with either \( \sim 4 \times 10^6 \) CFU of *E. faecalis* or \( 7-9 \times 10^6 \) CFU of *E. faecium* followed by tested drug, or PBS as control \( \sim 1 \) hour after inoculation. These inocula were chosen after an initial virulence pilot study of these strains, as they were able to kill at least 90% of the larvae within 72h. One group, injected twice with PBS, and one untouched group were used as controls in each experiment. All injections were performed with a volume of 10µL using a Hamilton syringe. After injection, *G. mellonella* were incubated at 37°C and survival was measured daily. Each experiment was repeated at least twice and representative experiments are presented. Any experiment with more than two dead larvae in any control group was discarded. Doses simulated free peak concentrations seen in humans of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid 600mg (Table 4). Gentamicin 1.3mg/kg and rifampin 300mg were also tested in combination with either linezolid or daptomycin 6mg/kg.

**Statistical Analysis.** For the in vitro model, changes in CFU/g at 8, 24, 48, and 72 hours and time to 99.9% kill were compared by two-way analysis of variance with Tukey’s Post-Hoc test. Statistical analyses were performed using SPSS Statistical Software (Release 20 SPSS, Inc., Chicago, IL). Survival in the *G. mellonella* model was plotted using Kaplan-Meier curves, and groups were compared using log-rank test (GraphPad Prism 5 software). For all experiments, a p value of \( \leq 0.05 \) was considered significant.
RESULTS

**Susceptibility testing.** Daptomycin, linezolid, gentamicin, and rifampin MICs for the two strains of enterococci are shown in Table 1. Against *E. faecalis*, there was minimal increase (1 and 2 dilutions respectively) in MICs with daptomycin and linezolid in the presence of high inocula. Against VRE *faecium*, there was an increase in the high inocula MICs of daptomycin and linezolid by 3 dilutions and 2 dilutions, respectively. There was minimal increase (0-2 dilution) in the gentamicin and rifampin MICs when the isolates were evaluated at high inocula. This is consistent with published studies. (10, 23).

**In vitro pharmacokinetics and pharmacodynamics.** The pharmacokinetic parameters of the antimicrobial agents were within the targeted range and can be found in Table 2. All obtained Cmax values were within 5% of targeted. The average and standard deviation of area under the concentration-time curve (AUC) for daptomycin 6mg/kg was $1028\pm36$, daptomycin 10mg/kg was $1430\pm47$, and linezolid was $348\pm16$.

**Biofilm production.** The *E. faecalis* isolate is a biofilm-positive control and produced consistent biofilm (++) at 24 and 48h. The *E. faecium* isolate did not produce biofilm (0) at 24 hours and was weakly adherent (+) at 48 hours.

**In vitro pharmacodynamic infection model with Simulated Endocardial Vegetations (SEVs).** The antimicrobial activity of daptomycin and linezolid were evaluated alone and in combination with gentamicin or rifampin against a high inoculum ($10^9$ CFU/g) of enterococci in a simulated IE vegetation model (Figure 1). Bactericidal activity ($\geq 3 \log_{10}$ decrease in CFU/g) was achieved by daptomycin 6 and 10mg/kg against *E. faecalis* at 24h and by daptomycin 10mg/kg against *E. faecium* at 8h. Linezolid monotherapy did not achieve bactericidal activity against either isolate tested at any time point. The AUC/MIC ratio for daptomycin 6mg/kg was 514-1028 (MIC range 1-2µg/mL), daptomycin 10mg/kg was 715-
1430 (MIC range 1-2µg/mL), and linezolid was 348 (MIC 1µg/mL). Percent time above the 
MIC (%T>MIC) was 100% for daptomycin and linezolid regimens.

Against biofilm-forming *E. faecalis*, daptomycin-containing regimens demonstrated 
significantly more activity (as measured by a decline in the mean CFU/g) than linezolid-
containing regimens from 8 hours through the end of the experiment (p≤0.005). (Figure 1a.)
Addition of gentamicin significantly increased activity for daptomycin 10mg/kg at 24h (95% CI  
0.954-3.4029; p=0.033). Addition of gentamicin to daptomycin 6mg/kg was significantly more  
active than any other regimen tested at 8h (p≤0.001). At 24h, there was a 3log_{10} CFU/g  
difference in activity between added gentamicin or rifampin to daptomycin 6mg/kg (p=0.010),  
though the difference was no longer significant at 48h. There was no significant difference  
between linezolid monotherapy and linezolid plus rifampin or gentamicin regimens at any  
time point during the 72h experiment, though adding rifampin to linezolid met the definition  
for improvement at 72h. Changing the schedule of rifampin dosing from 300mg three times  
daily to 900mg once daily had no effect on either regimen.

Against VRE *faecium*, at 24 and 48h, daptomycin-containing regimens had  
significantly (p≤0.005) more activity than any of the linezolid-containing regimens (Figure 1b).  
Addition of gentamicin improved linezolid activity, such that at 72h, linezolid plus gentamicin  
is only significantly different than daptomycin 6mg/kg (the most active regimen) (95%CI  
0.0144-3.4556, p=0.047) out of the daptomycin-containing regimens. It was not, however,  
significantly more active than linezolid monotherapy. The addition of gentamicin was  
significantly more active than the addition of rifampin with daptomycin 6mg/kg at 24h (95%CI  
0.2349-2.9984, p=0.013). Rifampin antagonized all regimens at 24h. Addition of rifampin also  
significantly antagonized linezolid activity at 48 and 72 hours (95%CI 0.0546-3.9921,  
p=0.040 and 95%CI 0.0595-4.1772, p=0.040). At 72h, activity of linezolid plus rifampin was  
not significantly different from the growth control. Changing rifampin dosing from three times
daily to once daily did not significantly increase activity, however linezolid plus rifampin once
daily was significantly more active than the growth control at 72h (95%CI 0.1546-4.6654,
p=0.028).

Gentamicin and rifampin monotherapy did not demonstrate any significant activity
against either isolate during the study. Resistance occurred in the rifampin and gentamicin
monotherapy models by 24h. The linezolid and daptomycin MICs varied at each time point
but never exceeded 4 µg/mL. In combination with both daptomycin and linezolid, rifampin
MICs increased throughout the 72h experiments against VRE, from 4 to >32 µg/mL.

Gentamicin MICs remained constant throughout the combination regimen experiments.

**In vivo Galleria mellonella survival assay.** Results demonstrated that all
antimicrobial regimens tested improved survival in all assays (p<0.0001) (Figures 2 and 3).
Against *E. faecalis*, monotherapy only with daptomycin 10mg/kg improved survival
significantly over linezolid alone (p=0.0032) (Figure 2a). Gentamicin added efficacy to
daptomycin 6mg/kg (p=0.0361), but not to linezolid (Figure 2 c and e), as observed in the in
vitro model. Against *E. faecium*, gentamicin added efficacy to both daptomycin 6mg/kg and
linezolid regimens (p=0.0009 and 0.0015) (Figure 3c and e). Addition of rifampin was not
significant for daptomycin or linezolid against either strain (Figure 2b, d, and 3b, d). Though
there was no antagonism observed for rifampin, other results concur with our IVPD findings.
DISCUSSION

Infective endocarditis vegetations often carry a high bacterial burden ($10^8$ - $10^{10}$ organisms per gram of tissue).(37) This high bacterial density and limited blood supply to this area allow for a diminished immune response and limited antimicrobial drug access. Location of the vegetation (right-sided versus left-sided endocarditis), patient comorbidities, and surgical interventions determine treatment success. (38, 39). The ability of bacteria to form biofilms may contribute to treatment failure, as these bacteria are inherently less susceptible to antibiotics due to decreased growth rates, nutrient restriction, and adaptive stress responses.(40-43)

Endocarditis cause by enterococci requires treatment with synergistic antimicrobials; traditionally, a cell wall active agent (beta-lactam or vancomycin) and an aminoglycoside. The presence of high-level resistance to vancomycin eliminates main therapeutic options in the management of serious enterococcal infections. Currently, options for resistant *E. faecalis* IE include ampicillin in combination with either imipenem/cilastatin or ceftriaxone.(1) While treatment with ampicillin in combination with ceftriaxone is becoming more common against high level aminoglycoside resistant (HLAR) *E. faecalis*, further investigations into PK/PD activity and dosage are needed. The 2005 American Heart Association Treatment of IE guidelines recommend $> 8$ weeks of linezolid or quinupristin/dalfopristin monotherapy for the treatment of *Native or Prosthetic Valve Enterococcal Endocarditis Caused by Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin*. (1) In many cases these treatments are not ideal; linezolid has inherent bacteriostatic activity (6, 44), myelosuppression (45, 46), and documented failure in animal studies and human case reports in bacteremia and IE. (47-50) Quinupristin/dalfopristin use is also limited as it demonstrates inherent bacteriostatic activity against VRE (51), lack of activity against *E. faecalis* (6), musculoskeletal toxicities in approximately 50% of the population, and the use of
a central line for administration. (52) Daptomycin is commonly used for the treatment of VRE infections (53), although the optimal dose and combinations are unknown.

Studies have shown that daptomycin demonstrates activity in enterococcal infections, and may provide an option in patients with allergies or contraindications to other therapies. In a retrospective cohort study of VRE bloodstream infections, treatment with daptomycin or linezolid demonstrated no difference in mortality; however, infection with *E. faecium* and concurrent treatment with rifampin or gentamicin were independent risk factors for mortality. (54) Antagonistic activity is often observed when rifampin is added to bactericidal agents in high inoculum infections, due to high rates of mutations conferring resistance (~1 in $10^6$). (31, 55, 56) The in vitro model demonstrated antagonism with rifampin. The in vivo model used a lower bacterial burden, so antagonism from rifampin resistance may not be as evident. In contrast, previous in vitro studies have shown synergy with daptomycin and rifampin, and non-antagonism with daptomycin and gentamicin. (6)

*G. mellonella* is an invertebrate model host that shares many of the advantages of mammalian models while being free of the ethical and logistical constraints that accompany their use. (57) Specifically, *G. mellonella* larvae can grow in 37°C thus effectively simulating human temperatures and can be directly injected with the tested inoculum and compounds thus allowing for exact quantification of the experimental concentrations. (58) As a result, this model host is well established in the screening of the efficacy and safety of antimicrobial compounds against a variety of infections (59), and has also been effectively used to test antibiotics against *Enterococcus* spp. in the past. (60) *G. mellonella* possess both cellular and humoral defenses and have extensive structural and functional similarities to vertebrate immune systems. (61) Finally, *G. mellonella* larvae have also been proven effective in identifying immunomodulatory properties of several compounds that would have otherwise gone unnoticed in in vitro experiments. (62) Our in vivo model demonstrated improvement
with addition of gentamicin to daptomycin 6mg/kg. It is possible that this improvement would not be seen with higher daptomycin doses, as survival was 100% at 9 days with the 10mg/kg dose.

Another in vitro model with simulated endocardial vegetations by Hall et al. successfully demonstrated the concentration-dependent activity of daptomycin against VRE, supporting doses >6mg/kg/day, as well as demonstrating daptomycin activity superior to that of linezolid.(32) A recent meta-analysis of VRE bacteremia demonstrated a trend toward increased survival with linezolid treatment over daptomycin.(63) These differences, however, were not statistically significant, and the studies used suffered from problems of different definitions of mortality, low doses of daptomycin (average dose ~6mg/kg), and a possible treatment selection bias in the cohorts.(64) A recent cohort study of patients with gram-positive infective endocarditis demonstrated no significant difference in mortality between standard of care antibiotics and daptomycin, given at an average of ~8mg/kg in the *E. faecalis* group.(65) The *E. faecalis* group treated with daptomycin had a significantly shorter length of stay compared to standard antibiotics (17.5 [13.5-19.5] vs. 31 [19.0-50.0]days, p=0.02).(65) Although small, this study also demonstrated no significant increase in adverse events with higher dose daptomycin. Our work demonstrates no statistically significant differences in any daptomycin regimen at 72h. High-dose daptomycin has some in vitro evidence to support its use in complicated enterococcal bacteremia and IE, as 10mg/kg, but not 6mg/kg, can prevent MIC increases in daptomycin non-susceptible *S. aureus* isolates.(66)

In conclusion, daptomycin-containing regimens generally were more active against enterococcal isolates than linezolid throughout the experiments. The addition of rifampin to either linezolid or daptomycin did not significantly increase antibacterial activity in an in vitro sequestered high inoculum model of enterococcal endocarditis at 72h, and rifampin delayed
the bactericidal activity of daptomycin during the first 24 hours. The inhibition of bacterial RNA synthesis may be responsible for delaying the killing activities of cell wall active agents.(67) The addition of gentamicin improved the bactericidal activity of daptomycin most in the first 24h against *E. faecalis*, and increased linezolid activity at 72h against VRE *faecium*. It is currently unclear how linezolid, a protein synthesis inhibitor, demonstrates improved activity in the presence of gentamicin. This improved activity has also been observed in *S. aureus* and a vancomycin-resistant *E. faecalis*.(67-69) We feel that our work supports the use of daptomycin 6 or 10mg/kg with 24 hours of gentamicin added for *E. faecalis*, as the most active therapy for enterococcal endocarditis. Other clinical studies demonstrate worse clinical outcomes when using rifampin in combination, while gentamicin adds activity in the first 24 hours only, and should be limited due to concerns for nephrotoxicity.

A limitation of this study is the use of limited isolates. In addition, we cannot conclude that our in vitro results will hold true with treatment durations longer than 72 hours. Our findings with daptomycin and linezolid monotherapy are consistent with published clinical, in vitro and animal models. (7, 32, 70) The linezolid concentration in *G. mellonella*, while active, was lower than desired due to limits on available pharmaceutical concentrations. It is possible that the differences seen would not be significant if a higher concentration were used. While *G. mellonella* received doses targeting the free peak concentration achieved in humans, each drug was dosed only once, with survival being measured over 9 days, and pharmacokinetic information including metabolism and excretion are unknown.

The results support daptomycin 6 or 10mg/kg, with gentamicin added for 24 hours, against enterococci in simulated endocardial vegetations. Nonetheless, our results should be applied to clinical practice with caution. Confirmation of these results in clinical studies is needed before these regimens can be adopted for use in the care of patients.
ACKNOWLEDGEMENTS

We thank Kayla Babcock for laboratory assistance. We gratefully acknowledge Christine Long, Core Laboratory Supervisor and Clyde Belgrave M.D., Chief of Laboratory Services at the Veterans Affairs Medical Center in Providence RI, for analysis of the gentamicin samples. We also gratefully acknowledge David P. Nicolau, Pharm.D.,FCCP and Christina Sutherland at the Center for Anti-Infective Research and Development at Hartford Hospital (Hartford, CT) for HPLC analysis of daptomycin concentrations and Charles Peloquin, Pharm.D. from University of Florida (Gainesville, FL) for HPLC analysis of the linezolid and rifampin samples.

Conflicts of Interest and Disclosures

The views expressed are those of the authors and do not necessarily reflect the position or policy of the United States Department of Veterans Affairs. All data collection, extraction, and analyses were carried out by the Department of Veterans Affairs study team. This research was funded in part by Cubist Pharmaceuticals. MKL: Cubist and Pfizer research funding. KLL: Cubist, Astellas, Theravance, Forest, Davol, Marvao, and Pfizer research funding, advisor, speaker, and/or consultancy.
REFERENCES


38. **Fowler VG, Jr., Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E,**


60. ***INVALID CITATION!!!***


<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>MIC in mg/L $^a$</th>
<th>$E. faecalis$</th>
<th>$E. faecium$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ATCC 29212</td>
<td>L2001</td>
<td></td>
</tr>
<tr>
<td>Daptomycin</td>
<td>2 (4)</td>
<td>1 (8)</td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>1 (4)</td>
<td>1 (4)</td>
<td></td>
</tr>
<tr>
<td>Gentamicin</td>
<td>16 (32)</td>
<td>16 (32)</td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td>0.5 (0.5)</td>
<td>4 (16)</td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>2</td>
<td>&gt;256</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ The standard inoculum was $5 \times 10^5$ CFU/mL, and the high inoculum was $5 \times 10^9$ CFU/mL. Data for the high inoculum are presented parenthetically.

NA = not applicable
<table>
<thead>
<tr>
<th>Regimen(^a)</th>
<th>Peak concentration (mg/L)</th>
<th>Half-life (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Targeted</td>
<td>Obtained</td>
</tr>
<tr>
<td>Daptomycin 6mg/kg q24h</td>
<td>98.6</td>
<td>102.5 ± 1.96</td>
</tr>
<tr>
<td>Daptomycin 10mg/kg q24h</td>
<td>140.0</td>
<td>143.2 ± 1.94</td>
</tr>
<tr>
<td>Linezolid 600mg q12h</td>
<td>21.0</td>
<td>21.9 ± 0.86</td>
</tr>
<tr>
<td>Gentamicin 1.3mg/kg q12h</td>
<td>6.0</td>
<td>5.7 ± 0.51</td>
</tr>
<tr>
<td>Rifampin 300mg q8h</td>
<td>10.5</td>
<td>11.0 ± 1.23</td>
</tr>
</tbody>
</table>

**TABLE 2.** Values of mean targeted and obtained pharmacokinetic parameters obtained with simulated endocarditis vegetations (SEV) infection models ± standard deviation

\(^a\)based on a 75 kg patient
TABLE 3. Inoculum change from starting inoculum of $5 \times 10^9$ CFU/g at 8, 24, and 72 h obtained in the SEV model. Note that positive values indicate growth.

*a Indicates statistically significant difference from growth control.

Mean change in bacterial density ($\log_{10}$ CFU/g)

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>E. faecalis</th>
<th></th>
<th></th>
<th>E. faecium</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8h</td>
<td>24h</td>
<td>72h</td>
<td>8h</td>
<td>24h</td>
<td>72h</td>
</tr>
<tr>
<td>Growth Control</td>
<td>+1.13</td>
<td>+1.06</td>
<td>+1.29</td>
<td>+1.82</td>
<td>+1.93</td>
<td>+1.86</td>
</tr>
<tr>
<td>Daptomycin 6mg/kg</td>
<td>-2.07</td>
<td>-4.28</td>
<td>-5.07</td>
<td>-2.11</td>
<td>-4.56</td>
<td>-5.86</td>
</tr>
<tr>
<td>Daptomycin 6mg/kg+ rifampin</td>
<td>-1.88</td>
<td>-2.99</td>
<td>-5.13</td>
<td>-1.84</td>
<td>-3.33</td>
<td>-5.30</td>
</tr>
<tr>
<td>Daptomycin 6mg/kg + gentamicin</td>
<td>-4.36</td>
<td>-6.02</td>
<td>-6.15</td>
<td>-2.38</td>
<td>-4.96</td>
<td>-5.05</td>
</tr>
<tr>
<td>Daptomycin 10mg/kg</td>
<td>-2.23</td>
<td>-4.17</td>
<td>-6.07</td>
<td>-3.57</td>
<td>-4.90</td>
<td>-5.63</td>
</tr>
<tr>
<td>Daptomycin 10mg/kg+ rifampin</td>
<td>-1.65</td>
<td>-3.48</td>
<td>-5.46</td>
<td>-2.09</td>
<td>-3.71</td>
<td>-5.41</td>
</tr>
<tr>
<td>Daptomycin 10mg/kg + gentamicin</td>
<td>-2.32</td>
<td>-6.07</td>
<td>-5.67</td>
<td>-2.99</td>
<td>-4.08</td>
<td>-5.04</td>
</tr>
<tr>
<td>Linezolid</td>
<td>+0.02</td>
<td>-0.19</td>
<td>-0.95</td>
<td>+0.07</td>
<td>-1.08</td>
<td>-2.90</td>
</tr>
<tr>
<td>Linezolid + rifampin</td>
<td>-0.07</td>
<td>-0.40</td>
<td>-1.96</td>
<td>+0.45</td>
<td>+0.48</td>
<td>-0.79</td>
</tr>
<tr>
<td>Linezolid + gentamicin</td>
<td>+0.13</td>
<td>-0.15</td>
<td>-0.88</td>
<td>-0.14</td>
<td>-0.67</td>
<td>-4.08</td>
</tr>
</tbody>
</table>
Figure 1. The activity (change in $\log_{10}$ CFU/g) of daptomycin- or linezolid- containing regimens against a) *Enterococcus faecalis* (vancomycin- susceptible, gentamicin- susceptible, rifampin- susceptible, daptomycin- susceptible, linezolid- susceptible) or b) *Enterococcus faecium* (vancomycin- resistant, gentamicin- susceptible, rifampin- resistant, daptomycin- susceptible, linezolid- susceptible).
Figure 3. Efficacy of compounds against E. faecalis on a G. mellonella infection model. Each line on the graph represents the survival of a group of 16 larvae injected with E. faecalis followed by injection of the relative drug. Survival proportion with a) monotherapy of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid vs controls. b) daptomycin 6mg/kg alone and in combination with rifampin. c) daptomycin 6mg/kg alone or in combination with gentamicin. d) linezolid alone or in combination with rifampin. e) linezolid alone or in combination with gentamicin.
Figure 4. Efficacy of compounds against *E. faecium* on a *G. mellonella* infection model. Each line on the graph represents the survival of a group of 16 larvae injected with *E. faecium* followed by injection of the relative drug. Survival proportion with a) monotherapy of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid vs controls. b) daptomycin 6mg/kg alone and in combination with rifampin c) daptomycin 6mg/kg alone or in combination with gentamicin d) linezolid alone or in combination with rifampin and e) linezolid alone or in combination with gentamicin.
<table>
<thead>
<tr>
<th>Antimicrobial and Human Dose</th>
<th>Targeted free peak concentration (mg/L)</th>
<th>Administered concentration in \textit{G. mellonella} (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daptomycin 6mg/kg</td>
<td>9.8</td>
<td>9.15</td>
</tr>
<tr>
<td>Daptomycin 10mg/kg</td>
<td>14.0</td>
<td>13.07</td>
</tr>
<tr>
<td>Linezolid 600mg</td>
<td>14.0</td>
<td>8.00(^a)</td>
</tr>
<tr>
<td>Gentamicin 1.3mg/kg</td>
<td>6.0</td>
<td>5.60</td>
</tr>
<tr>
<td>Rifampin 300mg</td>
<td>2.6</td>
<td>2.50</td>
</tr>
</tbody>
</table>

\(^a\) Linezolid concentrations were lower than targeted due to limits on the available pharmaceutical concentrations.

Table 4. Targeted vs. administered peak concentrations in \textit{G. mellonella} models.